Solid Biosciences reported significantly wider net losses for the nine months ended September 30, 2025, totaling $(124.5M) versus \((82.1M)\) in 2024. This was driven by a substantial 55.6% increase in R&D expenses to \(102.2M, heavily concentrated in the lead candidate SGT-003. Operating cash burn also increased to \)(102.7M)$.
Liquidity and Capital Structure: The company maintains a strong liquidity position, ending Q3 2025 with $236.1M in cash and marketable securities, projected to fund operations into the first half of 2027. This was bolstered by significant financing act
...